Loading
companiesCompany
Hanmi Pharmaceutical
Hanmi Pharmaceutical is one of South Korea's largest drug companies, known for its long-acting protein platform and for olmutinib, the third-generation EGFR inhibitor approved in Korea as Olita in 2016.
Also called: Hanmi Pharm한미약품KRX:128940
Overview
Hanmi Pharmaceutical, founded in 1973 and based in Seoul, is a research-driven South Korean pharmaceutical company. Its LAPSCOVERY platform produced efpeglenatide and the neutropenia drug eflapegrastim (Rolvedon), and it has out-licensed several oncology candidates including the pan-RAF inhibitor belvarafenib and the FLT3 inhibitor tuspetinib. Olmutinib (HM61713), a third-generation EGFR T790M inhibitor, received conditional approval in Korea in 2016; Boehringer Ingelheim returned its licence the same year after cases of severe skin toxicity.
Headquarters
Seoul, KR
Scorecard
All companies#479of 1244 companies, score 5
- targets +2
- modalities +2
- registry trials +4
- failures -3
0 approved, 0 in phase 3, 0 earlier, 1 targets, 4 registry studies. Formula on the scorecards page.
Type
Large pharma · KRX:128940
Stage
Public
Website
Founded
1973
WithdrawnOral third-generation EGFR kinase inhibitor
Olmutinib · Olita
Olmutinib was a Korean-developed EGFR pill approved in South Korea in 2016 for lung cancers that had developed the T790M resistance mutation, the same niche as osimertinib; severe skin reactions and osimertinib's success ended its development.
drugs
WithdrawnOral third-generation EGFR kinase inhibitor
Olmutinib · Olita
trials
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant MelanomaPhase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the LungPhase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy